{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T09:52:05Z","timestamp":1765619525341},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T00:00:00Z","timestamp":1370649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00125-013-2953-6","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T10:16:00Z","timestamp":1370600160000},"page":"1878-1883","source":"Crossref","is-referenced-by-count":34,"title":["Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?"],"prefix":"10.1007","volume":"56","author":[{"given":"M. A.","family":"Nauck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Baranov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Ritzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,8]]},"reference":[{"key":"2953_CR1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696\u20131705","journal-title":"Lancet"},{"key":"2953_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, \u00d8rskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741\u2013744","journal-title":"Diabetologia"},{"key":"2953_CR3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/(SICI)1096-9136(1998110)15:11<937::AID-DIA701>3.0.CO;2-0","volume":"15","author":"MA Nauck","year":"1998","unstructured":"Nauck MA, Weber I, Bach I et al (1998) Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2-diabetic patients. Diabet Med 15:937\u2013945","journal-title":"Diabet Med"},{"key":"2953_CR4","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2337\/diacare.21.11.1925","volume":"21","author":"MA Nauck","year":"1998","unstructured":"Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W (1998) Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21:1925\u20131931","journal-title":"Diabetes Care"},{"key":"2953_CR5","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.86.8.3853","volume":"86","author":"MB Toft-Nielsen","year":"2001","unstructured":"Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853\u20133860","journal-title":"J Clin Endocrinol Metab"},{"key":"2953_CR6","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/jc.2003-030049","volume":"88","author":"JJ Meier","year":"2003","unstructured":"Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719\u20132725","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"2953_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.regpep.2004.07.014","volume":"124","author":"MA Nauck","year":"2005","unstructured":"Nauck MA, Meier JJ (2005) Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 124 (Suppl):135\u2013148","journal-title":"Regul Pept"},{"key":"2953_CR8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diabetes.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Host JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126\u20131131","journal-title":"Diabetes"},{"key":"2953_CR9","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1152\/ajpendo.1996.271.3.E458","volume":"271","author":"CF Deacon","year":"1996","unstructured":"Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271:E458\u2013E464","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2953_CR10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s001250050613","volume":"39","author":"MA Nauck","year":"1996","unstructured":"Nauck MA, Wollschl\u00e4ger D, Werner J et al (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546\u20131553","journal-title":"Diabetologia"},{"key":"2953_CR11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","volume":"38","author":"R Ritzel","year":"1995","unstructured":"Ritzel R, \u00d8rskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720\u2013725","journal-title":"Diabetologia"},{"key":"2953_CR12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","volume":"22","author":"M-B Toft-Nielsen","year":"1999","unstructured":"Toft-Nielsen M-B, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137\u20131143","journal-title":"Diabetes Care"},{"key":"2953_CR13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2337\/diacare.24.4.720","volume":"24","author":"M Zander","year":"2001","unstructured":"Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24:720\u2013725","journal-title":"Diabetes Care"},{"key":"2953_CR14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824\u2013830","journal-title":"Lancet"},{"key":"2953_CR15","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2337\/diacare.27.8.1910","volume":"27","author":"M Zander","year":"2004","unstructured":"Zander M, Christiansen A, Madsbad S, Holst JJ (2004) Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 27:1910\u20131914","journal-title":"Diabetes Care"},{"key":"2953_CR16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-5491.2006.01800.x","volume":"23","author":"H Linnebjerg","year":"2006","unstructured":"Linnebjerg H, Kothare PA, Skrivanek Z et al (2006) Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med 23:240\u2013245","journal-title":"Diabet Med"},{"key":"2953_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","volume":"62","author":"OG Kolterman","year":"2005","unstructured":"Kolterman OG, Kim DD, Shen L et al (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62:173\u2013181","journal-title":"Am J Health Syst Pharm"},{"key":"2953_CR18","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/diacare.26.8.2370","volume":"26","author":"MS Fineman","year":"2003","unstructured":"Fineman MS, Bicsak TA, Shen LZ et al (2003) Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and\/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370\u20132377","journal-title":"Diabetes Care"},{"key":"2953_CR19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","volume":"20","author":"MS Fineman","year":"2004","unstructured":"Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD (2004) Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20:411\u2013417","journal-title":"Diabetes Metab Res Rev"},{"key":"2953_CR20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","volume":"30","author":"TJ Moretto","year":"2008","unstructured":"Moretto TJ, Milton DR, Ridge TD et al (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:1448\u20131460","journal-title":"Clin Ther"},{"key":"2953_CR21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092\u20131100","journal-title":"Diabetes Care"},{"key":"2953_CR22","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1210\/jc.2005-1093","volume":"90","author":"F Fehse","year":"2005","unstructured":"Fehse F, Trautmann M, Holst JJ et al (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991\u20135997","journal-title":"J Clin Endocrinol Metab"},{"key":"2953_CR23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1055\/s-2005-870529","volume":"37","author":"K Taylor","year":"2005","unstructured":"Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS (2005) Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 37:627\u2013632","journal-title":"Horm Metab Res"},{"key":"2953_CR24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-924230","volume":"114","author":"MA Nauck","year":"2006","unstructured":"Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J (2006) Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes : Off J German Soc Endocrinol German Diabetes Assoc 114:417\u2013423","journal-title":"Exp Clin Endocrinol Diabetes : Off J German Soc Endocrinol German Diabetes Assoc"},{"key":"2953_CR25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473\u2013481","journal-title":"Lancet"},{"key":"2953_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84\u201390","journal-title":"Diabetes Care"},{"key":"2953_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39\u201347","journal-title":"Lancet"},{"key":"2953_CR28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-59745-245-8_6","volume":"456","author":"A Giordano","year":"2008","unstructured":"Giordano A, Frontini A, Cinti S (2008) Adipose organ nerves revealed by immunohistochemistry. Methods Mol Biol 456:83\u201395","journal-title":"Methods Mol Biol"},{"key":"2953_CR29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.regpep.2009.04.004","volume":"156","author":"PM Hellstr\u00f6m","year":"2009","unstructured":"Hellstr\u00f6m PM (2009) GLP-1: broadening the incretin concept to involve gut motility. Regul Pept 156:9\u201312","journal-title":"Regul Pept"},{"issue":"609\u2013618","key":"2953_CR30","first-page":"e21","volume":"21","author":"J Schirra","year":"2009","unstructured":"Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, G\u00f6ke B (2009) GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 21(609\u2013618):e21\u2013e22","journal-title":"Neurogastroenterol Motil"},{"key":"2953_CR31","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1210\/jc.2010-2876","volume":"96","author":"Y Falk\u00e9n","year":"2011","unstructured":"Falk\u00e9n Y, Hellstr\u00f6m PM, Holst JJ, N\u00e4slund E (2011) Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96:2227\u20132235","journal-title":"J Clin Endocrinol Metab"},{"key":"2953_CR32","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","volume":"30","author":"BJ Goldstein","year":"2007","unstructured":"Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979\u20131987","journal-title":"Diabetes Care"},{"key":"2953_CR33","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2337\/dc06-1549","volume":"30","author":"B Laferrere","year":"2007","unstructured":"Laferrere B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709\u20131716","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-013-2953-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-013-2953-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-013-2953-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T19:03:03Z","timestamp":1563130983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-013-2953-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,8]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2953"],"URL":"https:\/\/doi.org\/10.1007\/s00125-013-2953-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,8]]}}}